Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could reusing your own blood during bypass surgery reduce transfusions?

NCT ID NCT06358079

Disease control Sponsor: Damascus University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 02, 2026 · Updated 2 times

Summary

This study tests whether collecting and re-infusing unwashed shed blood during off-pump coronary artery bypass surgery can reduce the need for donor blood transfusions and lower complications. Fifty adults undergoing this surgery will have their shed blood returned via a special circuit. Researchers will measure blood loss, transfusion needs, inflammation, and heart and brain markers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Re-infusion of unwashed shed blood via a cardiotomy circuit
What this could lead to
If successful, this could reduce the need for donor blood transfusions and lower complications during heart surgery.
What could go wrong
This is a small, early-stage study (50 participants) with no control group, so results may not be conclusive. Re-infusing unwashed blood carries risks of inflammation or other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

50 people

The number who actually took part.

Started

Mar 2024

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All patients undergoing isolated off-pump coronary artery bypass surgery between March 1st, 2024 and March 31st, 2026. Exclusion Criteria: * Missing data. * Patients outside the study period. * Patients under the age of 40 years or over the age of 75 years. * Patients with impaired left ventricular function (EF less the 40%). * Patients with history of renal failure, hepatic failure, CVA, or TIA. * Patients who have not stopped anticoagulants (except aspirin) for 4 days preoperatively. * Emergency operations.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blood transfusion complication are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiovascular disorder coronary artery disorder Transfusion Reaction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Blood transfusion complication Cardiovascular complication Coronary artery disease

Contacts and locations

Locations

  • Damascus University Cardiac Surgery Hospital

    Damascus, Syria

More trials for these conditions

Other studies related to the condition(s) this trial covers.